Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
32 hedge funds and large institutions have $20.9M invested in Telesis Bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 37 → 32 (-5)
20% less capital invested
Capital invested by funds: $26.1M → $20.9M (-$5.17M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$868K |
| 2 |
Renaissance Technologies
New York
|
+$284K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$229K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$177K |
| 5 |
PM
Penbrook Management
New York
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.28M |
| 2 |
FAM
Fred Alger Management
New York
|
-$275K |
| 3 |
RI
RTW Investments
New York
|
-$180K |
| 4 |
Millennium Management
New York
|
-$134K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$57K |
TBIO Hedge Fund Activity: Q3 2022 in Review
32 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q3 2022, worth a combined $20.9M — down 20% from $26.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TBIO and 6 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 6 added.
The largest buyer was Penn Capital Management, adding an estimated $868K. The largest seller was Franklin Resources, exiting entirely with an estimated $4.28M sold.
- 32 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q3 2022, down from 37 in Q2 2022.
- Funds reported $20.9M of Telesis Bio, Inc. Common Stock stock for Q3 2022, down 20% quarter-over-quarter.
- 6 funds opened new Telesis Bio, Inc. Common Stock positions in Q3 2022 and 11 closed out, a net change of -5 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q3 2022 was Penn Capital Management, an estimated $868K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q3 2022 was Franklin Resources, an estimated $4.28M sold.
Based on aggregated 13F filings for Q3 2022.